Identification of novel therapeutics for the treatment of neurodegenerative disorders
Neurimmune AG
Incorporated
08.11.2006Headquarters
SchlierenSupport
Illnesses such as Alzheimer’s and Parkinson’s disease remain as yet incurable. Neurimmune plans to change that by taking an unusual approach. This startup has not investigated the factors that lead to illnesses but rather has focused on those that keep us healthy. The company is applying this knowledge to identify novel therapeutics.
www.neurimmune.com
News
Positive progress in addressing unmet medical needs (startupticker.ch)
Clinical success for Neurimmune (startupticker.ch)
Biogen returns global IP rights on Alzheimer’s drug to Neurimmune (startupticker.ch)
Positive results for Swiss biotechs’ clinical studies (startupticker.ch)
Neurimmune and Ono Pharmaceutical collaborate in the field of neurodegenerative diseases (startupticker.ch)
Neurimmune and AstraZeneca join forces (startupticker.ch)
FDA approves Alzheimer’s drug of Neurimmune (startupticker.ch)
Neurimmune’s therapy against Alzheimer’s closer to approval (startupticker.ch)
Smart answers to the corona virus (startupticker.ch)
AL-S Pharma announces start of clinical trial (startupticker.ch)
Neurimmune to receive a milestone payment from Ono Pharmaceuticals (startupticker.ch)
Funds for Neurimmune to fight Alzheimer?s Disease (startupticker.ch)
Neurimmune to receive funding from its new partner from Japan (startupticker.ch)
Neurimmune raises $150 Million to finance its growth strategy (startupticker.ch)
Neurimmune raises $150 Million to finance its growth strategy (startupticker.ch)
Neurimmune Projekt mit Pfizer Forschungspreis ausgezeichnet (startupticker.ch)